Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Evoq Remedies Ltd - 543500 - Statement On Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Pursuant to Regulation 32 of the SEBI Listing Regulations and SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, please note that there are no deviation(s) or variation(s) in respect of the utilization of the proceeds of the Initial Public Offer ('IPO') of the Company during the Half Year ended 30th September, 2022, as mentioned in the object clause of the Prospectus dated 8th March, 2022 Please find enclosed herewith a statement in this regard. A statement confirming that there is no deviation or variation in the utilisation of these proceeds is enclosed herewith.
27-01-2023
Bigul

Evoq Remedies Ltd - 543500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 With reference to the captioned subject, we hereby submit the confirmation Certificate received from M/s. Accurate Securities & Registry Private Limited, Registrar and Share Transfer Agent (RTA) as per Regulation 74(5) of the Securities and Exchange Board India (Depository and Participant) Regulations, 2018 for the Quarter and Nine Months ended on 31st December, 2022.
09-01-2023
Bigul

Evoq Remedies Ltd - 543500 - Submission Of Revised Unaudited Financial Results For The Half Year Ended On 30Th September, 2022 Along With Limited Review Report

 In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Revised Unaudited Financial Results for the Half Year ended on 30th September, 2022 along with Limited Review Report. Kindly take this revised result on your record and oblige us. Thanking You. Yours Faithfully,
08-11-2022
Bigul

Evoq Remedies Ltd - 543500 - Submission Of Unaudited Financial Results For The Half Year Ended On 30Th September, 2022 Along With Limited Review Report

 In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Unaudited Financial Results for the half year ended on 30th September, 2022 along with Limited Review Report. Please take note of the same and oblige.
07-11-2022
Bigul

Evoq Remedies Ltd - 543500 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. 7Th November, 2022

 Pursuant to second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e. on 7th November, 2022 at the Registered Office of the Company, which commenced at 3:00 P.M. and concluded at 5:30 P.M. inter-alia, has to considered and approved as per attachment.
07-11-2022
Bigul

Evoq Remedies Ltd - 543500 - Update on board meeting

 Evoq Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2022 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that a meeting of the Board of Directors of the Company will be held on 7th November, 2022 at 3:00 P.M. at the registered office of the Company situated at A-1106, Empire Business Hub Near AUDA Water Tank, Science City Road, Sola Ahmedabad - 380 060 inter alia, to discuss and consider issue of Equity Shares of the Company on Rights basis, and also consider agenda intimated as on 15th October, 2022. Further, pursuant to Clause 4 of Schedule B of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and Company's Code of Internal Procedures and Conduct for Prevention of Insider Trading in Securities, this is to inform that the trading window for dealing in Equity Shares of the Company by the Insiders will be closed till 48 hours after the conclusion of the meeting.
01-11-2022
Bigul

Evoq Remedies Ltd - 543500 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 7Th November, 2022

 Evoq Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2022 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of the Company will be held on 7th November, 2022 at 3:00 P.M. at the registered office of the Company situated at A-1106, Empire Business Hub Near AUDA Water Tank, Science City Road, Sola Ahmedabad - 380 060 inter alia, to consider and approve the Unaudited Financial Results of the Company for the Half Year ended on 30th September, 2022 along with Limited Review Report. Please take note of the same and oblige.
15-10-2022
Bigul

Evoq Remedies Ltd - 543500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 With reference to the captioned subject, we hereby submit the confirmation Certificate received from M/s. Accurate Securities & Registry Private Limited, Registrar and Share Transfer Agent (RTA) as per Regulation 74(5) of the Securities and Exchange Board India (Depository and Participant) Regulations, 2018 for the Quarter and half year ended on 30th September, 2022. Kindly take the same on your record and oblige us. Thanking You
11-10-2022
Bigul

Evoq Remedies Ltd - 543500 - Statement Of Investor Complaints For The Quarter Ended September 2022

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Parth KamdarDesignation :- Company Secretary and Compliance Officer
11-10-2022
Bigul

Evoq Remedies Ltd - 543500 - Closure of Trading Window

 Pursuant to Clause 4 of Schedule B of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and Company's Code of Internal Procedures and Conduct for Prevention of Insider Trading in Securities, this is to inform that the trading window for dealing in Equity Shares of the Company by the Insiders will be closed from Saturday, 1st October, 2022 till 48 hours after the declaration and publication of Unaudited Financial Results for the Quarter and half year ended on 30th September, 2022. Please take note of the same and oblige.
30-09-2022
Next Page
Close

Let's Open Free Demat Account